A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

Inclusion Criteria:

• Informed consent from parent(s) or legally acceptable representative (LAR) and childassent from the subject obtained before any trial-related activities. Trial-relatedactivities are any procedures that are carried out as part of the trial, includingactivities to determine suitability for the trial.

• Male or female, aged 10 to below 18 years at the day of randomisation

• HbA1c 6.5%-11.0% (47-97 mmol/mol) (both inclusive)

• Diagnosed with type 2 diabetes mellitus according to the American DiabetesAssociation criteria and treated with:

• stable metformin dose (stable metformin dose is defined as at least 1000 mg daily orthe maximum tolerated dose for 56 days or longer prior to screening) or

• stable metformin dose and a stable dose of basal insulin (stable dose of basalinsulin is defined as basal insulin treatment equal to or more than 30 days prior toscreening, compared to the dose at screening, dose adjustments of ± 25% are allowed)or

• stable dose of basal insulin

Exclusion Criteria:

• Diagnosis of type 1 diabetes

• Maturity onset diabetes of the young (MODY)

• Positive insulinoma associated-protein 2 (IA-2) antibodies or anti-glutamic aciddecarboxylase (anti-GAD) antibodies.